Zur Rose Group accelerated bookbuilding with CHF 188.5 million gross proceeds

Zur Rose Group, e-commerce pharmacy and medical wholesalers, has concluded its accelerated bookbuilding (ABB) with the issuance of 650’000 new shares at an offer price of CHF 290 and gross proceeds of CHF 188.5 million. The shares were placed with institutional investors. BofA Securities and Jefferies acted as joint global coordinators and joint book runners for the ABB.

Zur Rose Group intends to use the gross proceeds from the capital increase to make full use of increasing market opportunities and to further support its growth strategy, based on three pillars: (i) extending leadership in technology, (ii) seizing the opportunities from e-prescriptions in Germany and (iii) pushing ahead with internationalization.

The new shares were issued on 10 December 2021 admitted for trading without a prospectus on the International Reporting Standard segment of SIX Swiss Exchange as of 13 December 2021.

Baker McKenzie advised Zur Rose Group on all legal aspects of the accelerated bookbuilding and capital increase. The team included partner Matthias Courvoisier (capital markets), senior associate Yves Mauchle (capital markets) and associate Tanja Schmid (capital markets).